Skip to content
Screener

Dianthus Therapeutics DNTH Financing Cash Flow

Financing Cash Flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
Amgen logo
AmgenAMGN
-$1.48B+44.6%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$1.21M+104%
Vor Biopharma logo
Vor BiopharmaVOR
$74.87M+12,455%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.1M+195%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
$128.01M

Other financials

Income statement

See full
Revenue$396.0K-81.8%
Operating income-$46.5M-40.3%
Net income-$40.8M-38.4%
EPS (diluted)-$0.85-3.7%

Balance sheet

See full
Cash & equivalents$627.7M+6,105%
Total debt$1.4M-2.3%
Total equity$1.2B+266%
Total assets$1.2B+258%

Cash flow

See full
Operating cash flow-$28.9M-4.4%
CapEx$10.0K-58.3%
Free cash flow-$28.9M-4.4%

Valuation

See full
Market cap$6.09B+902%
Enterprise value$5.47B+817%

Profitability

See full
Operating margin-4,558.4%-9,354pp
Net margin-4,104.8%-7,304pp
FCF margin-3,561.6%-6,956pp

Returns & leverage

See full
Return on equity-28.6%+3.2pp
Debt / equity0.0×
Current ratio29.3×+13.3×

Where this comes from

Reported directly by Dianthus Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001690585-26-000022
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from exercise of stock options (net of receivable for stock option proceeds in transit)4,27731
Proceeds from issuance of common stock under employee stock purchase plan120129
Proceeds from exercise of warrants and pre-funded warrants11
Net cash provided by financing activities739,410161
Increase/(decrease) in cash, cash equivalents and restricted cash576,581(12,675)
Cash, cash equivalents and restricted cash, beginning of period51,25423,022
Cash, cash equivalents and restricted cash, end of period$627,835$10,347
Supplemental Disclosure

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Dianthus Therapeutics's financing cash flow?
Dianthus Therapeutics (DNTH) reported financing cash flow of $739.41M in Q1 2026.
How has Dianthus Therapeutics's financing cash flow changed year-over-year?
Dianthus Therapeutics's financing cash flow increased by 459160.9% year-over-year, from $161K to $739.41M.
What is the long-term trend for Dianthus Therapeutics's financing cash flow?
Over 3 years (2021 to 2024), Dianthus Therapeutics's financing cash flow has grown at a 42.2% compound annual growth rate (CAGR), from $89.6M to $257.82M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Dianthus Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude